Roivant Sciences director Melissa B. Epperly forfeited 2,179 shares at $40.94 per share on September 10, 2026. The transaction matters to investors because it represented about 12.8% of her prior Roivant holding, while her post-transaction position stood at 14,838 shares.
Key Highlights
- The filing reports transaction code F for the event.
- Melissa B. Epperly held 14,838 Roivant Sciences shares after the transaction.
- The forfeited shares represented about 12.8% of her prior holding.
Roivant Sciences Ltd. (NASDAQ: ROIV) director Melissa B. Epperly forfeited 2,179 shares at $40.94 per share. The transaction took place on September 10, 2026.
Transaction Classified Under Code F
The filing reports transaction code F. Epperly was identified as a director of Roivant Sciences Ltd. The transaction involved shares of Roivant Sciences. Epperly’s balance after the event was 14,838 shares.
Forfeiture Represented About 12.8% of Prior Holding
The forfeited shares represented about 12.8% of Epperly’s prior shareholding. The 14,838-share balance reflects her position after the forfeiture.
FAQs
Q: Why did Melissa Epperly forfeit Roivant Sciences shares?
A: It reports transaction code F and records the forfeiture of 2,179 shares at $40.94 per share.
Q: How many Roivant shares did Melissa Epperly retain?
A: Following the transaction, Melissa B. Epperly owned 14,838 Roivant Sciences shares. The filing reports that the transaction occurred on September 10, 2026.
Q: What percentage of Melissa Epperly’s holdings did the transaction represent?
A: The 2,179-share forfeiture represented about 12.8% of Melissa B. Epperly’s prior Roivant Sciences shareholding. The disclosed comparison uses her position before the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.